Abstract
Ftorafur, 1-(2-tetrahydrofuryl)-5-fluorouracil, is a cancer drug very widely used in treatment of cancer in Japan; in particular, it is administered orally for treatment of tumors of the gastrointestinal tract. Recently a new preparation with an enteric coating became available for oral administration. Ftorafur itself is absorbed mainly from the jejunum and ileum, and slightly from the duodenum, but not from the stomach. This new preparation was designed to release ftorafur only in the intestine, and in experiments with beagle dogs it was shown to be absorbed more easily than the earlier preparation. With the same dose, approximately 20% greater total absorption into the blood was estimated with the new preparation. In clinical trials, side effects of the new preparation, especially to the upper digestive organs, were less evident than those of the previous one, which released nearly 100% ftorafur into the stomach within 10 min after the oral administration. The new preparation was tolerated by patients at daily doses of approximately 1 000 mg/m2 for continuous treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and l-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69:763–772
Garattini S (1971) Tumours and drug metabolism (General remarks). Proceeding of a seminar in clinical oncology. Padova, Sept 1971, pp 1–6
Hoshi A, Iigo M, Nakamura A, Yoshida M, Kuretani K (1976) Antitumor activity of l-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors. Gann 67:725–731
Iigo M, Hoshi A, Nakamura A, Kuretani K (1978) Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors. Cancer Chemother Pharmacol 1:203–208
Iigo M, Hoshi A, Nakamura A, Kuretani K (1978) Antitumor activity of 1-hexylcarbam-oyl-5-fluorouracil in Lewis lung carcinoma and B16 melanoma. J Pharm Dyn 1:49–54
Iigo M, Nakamura A, Kuretani K, Hoshi A (1979) Distribution l-hexylcarbamoyl-5-fluorouracil and 5–fluorouracil by oral administration in mice. J Pharm Dyn 2:5–11
Jato JG, Lake LM, Grunden EE, Johnson BM (1975) Effect of deoxyuridine coadministration on toxicity and antitumor activity of fluorouracil and floxuridine. J Pharm Sci 64:943–946
Jato J, Windheuser JJ (1973) 5-Fluorouracil and derivatives in cancer chemotherapy. III: In vivo enhancement of antitumor activity of 5-fluorouracil and 5-fluoro-2’-deoxyuridine. J Pharm Sci 62:1975–1978
Kobari T, Tan K, Kumakura M, Watanabe S, Shirakawa I, Kobayashi H, Ujiie A, Miyama Y, Namekawa H, Yamamoto H (1978) Metabolic fate of l-hexylcarbamoyl-5-fluorouracil in rats. Xenobiotica 9:547–556
Koyama Y, Hufu Clinical Group (to be published) Phase I study of a new drug, l-hexylcarbamoyl-5-fluorouracil (HCFU) by oral administration. Cancer Treat Rep
Ozaki S, Mizuno H, Ishikawa K, Mori H (1977) 5-Fluorouracil derivatives. I. The synthesis of l-carbamoyl-5-fluorouracils. Bull Chem Soc Jpn 50:2406–2412
Toide H, Akiyoshi H, Minato Y, Okuda H, Fujii S (1977) Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 68:553–560
Tsuruo T (unpublished work) Antitumor effect of l-hexylcarbamoyl-5-fluorouracil on mouse colon tumors
Vogel SJ, Presant CA, Ratkin GA, Klahr C (1979) Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma. Cancer Treat Rep 63:1–5
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sakurai, Y. (1981). Studies of Analogs of Fluorinated Pyrimidine in Japan. In: Carter, S.K., Sakurai, Y., Umezawa, H. (eds) New Drugs in Cancer Chemotherapy. Recent Results in Cancer Research, vol 76. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81565-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-81565-2_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81567-6
Online ISBN: 978-3-642-81565-2
eBook Packages: Springer Book Archive